文献速递精神分裂症与精神病性障碍儿童青少年精神

氯氮平、复发与不良事件:加拿大一项为期10年的电子队列研究

Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada.
PubMed 文献 · Br J Psychiatry · 2024-01-01

该研究基于加拿大不列颠哥伦比亚、曼尼托巴和萨斯喀彻温三省2008至2018年因精神健康问题首次住院的成人(n=45 616)和儿童/青少年(n=1476)数据,比较氯氮平与其他抗精神病药在复发再住院和不良事件再住院上的相对率。成人中氯氮平与较低的复发率相关,但不良事件风险较高;儿童/青少年中氯氮平与较低的复发率相关,且不良事件无差异。

要点

  • 成人中氯氮平与较低的复发率相关(校正HR 0.86,95%CI 0.83-0.90),但不良事件风险较高(HR 1.34,95%CI 1.18-1.54)。
  • 儿童/青少年中氯氮平与较低的复发率相关(校正HR 0.62,95%CI 0.49-0.78),不良事件与其他抗精神病药无差异。
  • 成人中氯氮平复发率在前21个月较高,之后逆转。

核心结论

  • 成人中氯氮平与较低的总体复发率相关,但伴随较高的不良事件风险。
  • 儿童/青少年中氯氮平在整个随访期间与较低的复发率相关,且不良事件与其他抗精神病药无差异。

研究设计与样本

  • 研究为基于加拿大不列颠哥伦比亚、曼尼托巴和萨斯喀彻温三省2008至2018年电子健康数据的队列研究。
  • 成人队列n=45 616,儿童/青少年队列n=1476,均为因精神健康问题首次住院的患者。
  • 将患者人口学特征和住院记录与首次就诊后配发的抗精神病药处方链接,采用复发事件生存分析比较氯氮平与其他抗精神病药。

主要发现

  • 成人中氯氮平与其他药物相比,10年随访期间复发率低14%(校正HR 0.86,95%CI 0.83-0.90)。
  • 成人中前21个月氯氮平复发率较高,之后逆转。
  • 成人中每1000人月,氯氮平治疗者预计有38次复发住院,其他药物为45次。
  • 儿童/青少年中氯氮平与其他抗精神病药相比,随访期间复发率低38%(校正HR 0.62,95%CI 0.49-0.78)。
  • 儿童/青少年中每1000人月,氯氮平为29次住院,其他药物为48次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clozapine is the most effective medication for treatment-resistant psychoses, but the balance of benefits and risks is understudied in real-world settings. AIMS: To examine the relative re-hospitalisation rates for mental health relapse and adverse events associated with clozapine and other antipsychotics in adult and child/youth cohorts. METHOD: Data were obtained from the Canadian Institute of Health Information for adults (n = 45 616) and children/youth (n = 1476) initially hospitalised for mental health conditions in British Columbia, Manitoba and Saskatchewan from 2008 to 2018. Patient demographics and hospitalisations were linked with antipsychotic prescriptions dispensed following the initial visit. Recurrent events survival analysis for relapse and adverse events were created and compared between clozapine and other antipsychotics. RESULTS: In adults, clozapine was associated with a 14% lower relapse rate versus other drugs (adjusted hazard ratio: 0.86, 95% CI: 0.83-0.90) over the 10-year follow-up. In the first 21 months, the relapse rate was higher for clozapine but then reversed. Over 1000 person-months, clozapine-treated adults could be expected to have 38 relapse hospitalisations compared with 45 for other drugs. In children/youth, clozapine had a 38% lower relapse rate compared with other antipsychotic medications (adjusted hazard ratio: 0.62, 95% CI: 0.49-0.78) over the follow-up period. This equates to 29 hospitalisations for clozapine and 48 for other drugs over 1000 person-months. In adults, clozapine had a higher risk for adverse events (hazard ratio: 1.34, 95% CI: 1.18-1.54) over the entire follow-up compared with other antipsychotics. This equates to 1.77 and 1.30 hospitalisations over 1000 person-months for clozapine and other drugs, respectively. CONCLUSIONS: Clozapine was associated with lower relapse overall, but this was accompanied by higher adverse events for adults. For children/youth, clozapine was associated with lower relapse all throughout and had no difference in adverse events compared with other antipsychotics.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Balbuena L, Halayka S, Lee A, et al. Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada. Br J Psychiatry. 2024. PMID: 39291442. doi:10.1192/bjp.2024.140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。